Prediction of erectile function following treatment for prostate cancer

JAMA

Volumn 306, Issue 11, 2011, Pages 1205-1214

  Alemozaffar, Mehrdad ^a   Regan, Meredith M ^a   Cooperberg, Matthew R ^b   Wei, John T ^c   Michalski, Jeff M ^d   Sandler, Howard M ^e   Hembroff, Larry ^f   Sadetsky, Natalia ^b   Saigal, Christopher S ^g   Litwin, Mark S ^g   Klein, Eric ^h   Kibel, Adam S ^d   Hamstra, Daniel A ^c   Pisters, Louis L ^j   Kuban, Deborah A ^j   Kaplan, Irving D ^a   Wood, David P ^c   Ciezki, Jay ⁱ   Dunn, Rodney L ^c   Carroll, Peter R ^b   Sanda, Martin G ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Glickman Urological and Kidney Institute   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BODY MASS; BRACHYTHERAPY; CONTROLLED STUDY; ERECTILE DYSFUNCTION; ETHNIC DIFFERENCE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PENIS PROSTHESIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RACE DIFFERENCE; SEXUAL INTERCOURSE;

EID: 80053065502     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1333     Document Type: Article

References (40)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. (Pubitemid 28445094)
2. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma: results from the Prostate Cancer Outcomes Study. Cancer. 2003;97(7):1653-1662. (Pubitemid 36350709)
3. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostatecancer survivors. N Engl J Med. 2008;358(12):1250- 1261. (Pubitemid 351439226)
4. Ferrer M, Suárez JF, Guedea F, et al Multicentric Spanish Group of Clinically Localized Prostate Cancer. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):421-432.
5. Madalinska JB, Essink-Bot ML, De Koning HJ, Kirkels WJ, Van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001; 19(6):1619-1628. (Pubitemid 32230861)
6. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92(19):1582-1592.
7. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129-135.
8. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009;339:b4817.
9. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008;180(6):2415-2422.
10. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. 1991;145(5):998-1002.
11. Briganti A, Capitanio U, Chun FK, et al. Prediction of sexual function after radical prostatectomy. Cancer. 2009;115(13)(suppl):3150-3159.
12. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164(6):1929-1934.
13. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354-360. (Pubitemid 30051753)
14. Nelson CJ, Choi JM, Mulhall JP, Roth AJ. Determinants of sexual satisfaction in men with prostate cancer. J Sex Med. 2007;4(5):1422-1427. (Pubitemid 47337689)
15. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21(21):3979-3986. (Pubitemid 46606212)
16. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134-1141. (Pubitemid 44288788)
17. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245-1250.
18. Miller DC, Wei JT, Dunn RL, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology. 2006;68(1):166-171. (Pubitemid 44037748)
19. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36(7):1002-1012. (Pubitemid 128456439)
20. Lubeck DP, Litwin MS, Henning JM, et al; CaPSURE Research Panel. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology. 1996;48(5):773-777. (Pubitemid 26398700)
21. Cooperberg MR, Broering JM, Litwin MS, et al; CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the prostate Strategic Urologic Research Endeavor (CapSURE), a national disease registry. J Urol. 2004;171(4):1393-1401. (Pubitemid 38365382)
22. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachy-therapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009;27(5):607-612.
23. Chen RC, Clark JA, Talcott JA. Individualizing quality- of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27(24):3916-3922.
24. Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol. 2003;170(4, pt 1):1291-1294. (Pubitemid 37108135)
25. Schover LR, Fouladi RT, Warneke CL, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer. 2002;95(11):2397-2407. (Pubitemid 35351148)
26. Prasad MM, Prasad SM, Hevelone ND, et al. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer. J Sex Med. 2010;7(3):1062-1073.
27. Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by men treated for localized prostate cancer. J Urol. 2009;182(2):649-654.
28. Hu JC, Elkin EP, Pasta DJ, et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2, pt 1):703-708.
29. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol. 2003;169(4):1453-1457. (Pubitemid 36323806)
30. Pinkawa M, Fischedick K, Asadpour B, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):83-89. (Pubitemid 350251028)
31. Ahlering TE, Kaplan AG, Yee DS, Skarecky DW. Prostate weight and early potency in robot-assisted radical prostatectomy. Urology. 2008;72(6):1263-1268.
32. Karakiewicz PI, Bhojani N, Neugut A, et al. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. J Sex Med. 2008;5(4):919-927. (Pubitemid 351472202)
33. Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int. 2008;101(7):833-836. (Pubitemid 351347727)
34. Michl UH, Friedrich MG, Graefen M, Haese A, Heinzer H, Huland H. Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol. 2006;176(1):227-231. (Pubitemid 43815418)
35. Bolla M, De Reijke TM, Van Tienhoven G, et al; EORTC Radiation Oncology Group and Genito- Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516-2527.
36. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol. 2005;173(5):1701-1705. (Pubitemid 40524809)
37. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009;101(12):888-892.
38. Schroeck FR, Donatucci CF, Smathers EC, et al. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008;113(10):2687-2694.
39. Levinson AW, Ward NT, Sanda MG, et al. Comparison of validated instruments measuring sexual function in men. Urology. 2010;76(2):380-386.
40. Chang P, Szymanski KM, Dunn RL, et al. Expanded Prostate Cancer Index Composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer [published online ahead of print July 23, 2011]. J Urol. doi:10.1016/j.juro.2011.04.085.